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Introduction
Thoracic aortic aneurysm and dissection (TAAD) is a major cardiovascular health problem that arises from 
mutations that alter vascular extracellular matrix (ECM), smooth muscle cell function, or growth factor sig-
naling pathways (1). In contrast to abdominal aortic aneurysms, TAAD has a strong genetic component, 
with pathogenic variants typically inherited in an autosomal dominant manner (2). A single highly pene-
trant, pathogenic mutation is responsible for disease in only one-fourth of  individuals with TAAD, indicating 
that other undiscovered genetic factors influence disease onset and progression. In addition to the known 
pathogenic gene mutations, low-penetrant risk variants interact with other genetic or environmental factors to 
trigger disease or to increase the risk for developing disease but are not themselves pathogenic (2). Significant 
risk factors for TAAD, primarily when occurring in the background of  low-penetrant disease-predisposing 
variants, are hypertension and bicuspid aortic valve (1).
A common histopathological feature of  TAAD in humans is fragmented elastin in the aortic medial 
region (3). Elastin is the most abundant ECM protein in the aorta, where it plays a central role in the vessel’s 
ability to expand and recoil in response to pulsatile blood flow. Smooth muscle cells (SMCs) synthesize and 
organize the protein into fenestrated sheets (lamellae) that separate smooth muscle cell layers. The secreted 
form of  elastin (tropoelastin) undergoes extensive crosslinking outside the cell to form an elastic polymer, 
which is the functional form of  the protein. The enzyme responsible for initiating crosslink formation is lysyl 
oxidase (LOX), a copper-binding amine oxidase that oxidizes lysine ε-amino groups in elastin and fibrillar 
collagens to aldehydes, which then spontaneously react to form covalent linkages between and within pro-
teins (4, 5). Approximately 90% of  the lysine residues in elastin undergo crosslink formation, which makes 
it one of  the most highly crosslinked and most stable proteins in the body (4). Inactivation of  the Lox gene 
Heterozygous missense mutations in lysyl oxidase (LOX) are associated with thoracic aortic 
aneurysms and dissections. To assess how LOX mutations modify protein function and lead 
to aortic disease, we studied the factors that influence the onset and progression of vascular 
aneurysms in mice bearing a Lox mutation (p.M292R) linked to aortic dilation in humans. We 
show that mice heterozygous for the M292R mutation did not develop aneurysmal disease unless 
challenged with increased hemodynamic stress. Vessel dilation was confined to the ascending 
aorta, although in both ascending and descending aortae, changes in vessel wall structure, smooth 
muscle cell number, and inflammatory cell recruitment differed between WT and mutant animals. 
Studies with isolated cells revealed that M292R-mutant LOX is retained in the endoplasmic 
reticulum and ultimately cleared through an autophagy/proteasome pathway. Because the mutant 
protein does not transit to the Golgi, where copper incorporation occurs, the protein is never 
catalytically active. These studies show that the M292R mutation results in LOX loss of function 
due to a secretion defect that predisposes the ascending aorta in mice (and by extension humans 
with similar mutations) to arterial dilation when exposed to risk factors that impart stress to the 
arterial wall.
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in mice results in early postnatal death due to ruptured aortic aneurysms, emphasizing the critical role of  
fully crosslinked, functional elastin in maintaining aorta integrity and function (6, 7). The gene inactivation 
studies also show that other LOX isoforms cannot substitute for the loss of  LOX in large, elastin-rich vessels.
LOX in vertebrates belongs to a family of  5 copper-dependent enzymes (LOX, LOXL1–4) that show 
a high degree of  homology in their carboxy-terminal catalytic domain but differ in their amino-termi-
nal sequences. LOXL2–4 form a subgroup that shares 4 amino-terminal scavenger receptor cysteine-rich 
domains that influence substrate binding but appear to have little role in regulating catalytic activity (8, 
9). LOX and LOXL1, in contrast, are synthesized without scavenger receptor sequences but have a pro-
peptide domain that keeps the enzymes in a latent state until proteolytically processed outside the cell by 
BMP1/Tolloid-like metalloproteinases (10, 11). Substrate specificity for each of  the lysyl oxidases is still 
under investigation, but gene inactivation studies and phylogenetic analysis suggest that LOX and LOXL1 
contribute to crosslinking of  elastin and fibrillar collagens, whereas LOXL2–4 have different substrate spec-
ificities (12, 13). All 5 LOX isoforms are synthesized in the ER and traffic to the Golgi, where the inactive 
apoenzyme binds copper and forms the cofactor lysyl tyrosine quinone (LTQ); both copper and LTQ are 
essential active site components required for catalytic activity (14).
Mutations within LOX in families with TAAD were recently identified by whole exome sequencing (3, 
15). Aortic disease in these families followed autosomal dominant inheritance, suggesting that 1 mutant 
LOX allele is sufficient to influence disease initiation or progression. Previously, we identified a LOX cata-
lytic site mutation (p.Met298Arg) in a family with a history of  TAAD (3). By introducing this human muta-
tion into the homologous position in the mouse genome using CRISPR/Cas9 genome editing technology 
(c.857T>G encoding p.M292R; hereafter referred to as Mu), we confirmed that this amino acid change 
caused ruptured TAAD and perinatal death when both alleles were mutated (LoxMu/Mu) (3). In contrast to 
humans who developed TAAD when heterozygous for this LOX variant, aneurysms or other arterial dis-
ease were not observed in mice with a similar genotype (Lox+/Mu) unless they were challenged with hyper-
tension. In this report, we show that the nature of  the functional loss associated with the methionine-to-ar-
ginine change in LOX results from a secretion defect, where the protein is retained in the ER and degraded 
through an autophagy/proteasome pathway. We also show that the vessel wall alterations associated with 
LOX functional haploinsufficiency increase the likelihood of  developing vascular disease in association 
with environmental factors that increase wall stress.
Results
Lox+/Mu adult animals are predisposed to aortic dilation in response to hypertension. The generation and char-
acterization of  mice expressing the M292R mutation were described previously (3). Mice heterozygous 
for this Lox missense variant appear grossly normal, have normal blood pressure, and show no increased 
mortality through 2 years of  age. Aortic diameter and circumferential wall stiffness at physiological 
blood pressure in Lox+/Mu animals are normal, but ascending aortic length measured from the aortic root 
to the brachiocephalic artery is 10% longer than in WT mice (3).
Hypertension is a known risk factor associated with aortic dilation (16). To test whether mice express-
ing mutant LOX are predisposed to aneurysm formation as a consequence of  increased wall stress, Lox+/Mu 
mice were made hypertensive by subcutaneous delivery of  angiotensin II (Ang II) via Alzet osmotic pumps. 
Pumps containing saline served as the control. Ang II infusion is a well-established model for inducing 
vessel wall changes in mice and other animals (17, 18). Blood pressure measurements using radiotelemetry 
in awake, freely moving Lox+/+ and Lox+/Mu mice showed an increase of  approximately 30 mmHg in systolic 
pressure and 25–30 mmHg in mean blood pressure in both genotypes 7–10 days after pump implantation 
(data not shown), consistent with what others have found using this model (19). After 4 weeks of  treatment, 
all animals receiving Ang II had cardiac hypertrophy, indicating altered cardiac physiology consistent with 
Ang II–induced hypertension (Figure 1A). However, only Lox+/Mu mice showed substantial dilation and 
elongation of  the ascending aorta in response to Ang II; no change in aortic diameter was observed in Ang 
II–treated Lox+/+ mice or in Lox+/Mu mice infused with saline alone (Figure 1B). Biaxial pressure-diameter 
testing showed the ascending aorta in Ang II–treated Lox+/Mu animals to be approximately 25% larger than 
the aorta from WT or saline-treated controls at mean physiological blood pressure (Figure 1C). The shape 
of  the pressure-diameter curves suggests that Ang II treatment did not affect aortic mechanical properties 
in either mutant or WT animals. Other than in the ascending aorta, no dilation or change in vessel mechan-
ics occurred in the left common carotid artery for either Lox+/+ or Lox+/Mu animals with saline or Ang II 
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treatment (Figure 1D), nor were dilations or areas of  stenosis found in the aortic arch, descending aorta, 
or abdominal aorta.
Ang II treatment leads to vessel wall thickening and changes in vascular cellularity. On a structural level, Ang 
II treatment resulted in ascending and descending aortic wall thickening in Lox+/Mu animals, but there were 
no changes in elastic lamellar number or lamellar organization, quantified by measurement of  medial area 
(Figure 2A and Supplemental Figure 1A; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.127748DS1). Elastic lamellar fragmentation, already elevated in Lox+/Mu com-
pared with Lox+/+ animals (3), did not increase in either genotype following Ang II treatment (data not 
shown). We analyzed elastin crosslinking using an ELISA assay for desmosine, a major crosslink in elastin. 
We found no difference in desmosine levels in aortic tissue from Lox+/+ and Lox+/Mu mice, confirming nor-
mal elastin levels and that elastin crosslinking is not affected in animals heterozygous for the Lox mutation 
(Supplemental Figure 1C). Hydroxyproline levels (as a measure of  total collagen) trended higher in vessels 
from the mutant animals but were not significantly different from WT when normalized to the change in 
total protein (Supplemental Figure 1D). Higher protein quantities are consistent with the increase in wall 
thickness that occurred with Ang II treatment (Supplemental Figure 1B).
Changes in the number and types of  cells were observed in the thickened aortic wall of  the hyperten-
sive animals. The most substantial change occurred in the adventitia of  both the ascending and descending 
aorta, which underwent considerable expansion in the Lox+/+ and Lox+/Mu animals as a result of  Ang II 
exposure (Figure 2A). In the medial layer, Ang II infusion led to a decrease in the number of  SMCs in 
Lox+/+ animals but an increase in SMCs in Lox+/Mu mice (Figure 2B). There was also an increase in intral-
amellar area in both genotypes, although the change was most notable in Lox+/Mu mice. The nuclei of  the 
intralamellar cells in the mutant media were rounder than cells in Lox+/+ vessels, suggesting a less polarized 
Figure 1. The ascending aorta in Lox+/Mu animals undergoes aortic dilation in response to hypertension. (A) Both 
Lox+/+ and Lox+/Mu animals developed significant cardiac hypertrophy following 4 weeks of treatment with 2 μg/kg/
min Ang II compared with saline-treated controls. Two-way ANOVA with Tukey’s multiple-comparisons test, with 
the 2 variables being genotype and treatment, was used to assess differences. Data are presented as mean ± SD. 
****P < 0.0001. (B) The ascending aorta in Lox+/Mu animals is longer than in Lox+/+ animals and undergoes substantial 
dilation following Ang II treatment. (C) Pressure-diameter measurements at intraluminal pressures ranging from 0 
to 175 mmHg. The ascending aorta from Ang II–treated Lox+/Mu animals has a larger diameter over the entire range 
of pressures compared with Lox+/+ animals treated with Ang II or with saline controls. (D) There was no difference in 
the diameter or mechanical properties of the left common carotid artery in either genotype with or without Ang II 
treatment. Repeated measures 2-way ANOVA with Tukey’s multiple-comparisons test was used to assess differences 
between groups at each pressure level. Data are presented as mean ± SD. #P < 0.05, Lox+/+ with Ang II vs. Lox+/Mu with 
Ang II; *P < 0.05, **P < 0.01, Lox+/Mu with saline vs. Lox+/Mu with Ang II. 
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phenotype and noncircumferential orientation. Immunostaining for smooth muscle α-actin demonstrated 
uniform reactivity throughout the medial intralamellar spaces, whereas cell staining in the adventitia was 
heterogeneous (not shown).
Staining for the monocyte/macrophage marker CD68 in descending aorta showed an increased number 
of CD68+ cells in the media and adventitia of both Lox+/+ and Lox+/Mu descending aorta following Ang II treat-
ment (Figure 2C). These results are consistent with previous studies showing that infusion of Ang II promotes 
macrophage accumulation within the aortic wall (20). While the adventitia showed the highest level of immune 
cell infiltration, macrophage accretion in the medial layer was also observed, but the spatial localization of the 
CD68+ cells was different for the 2 genotypes. In Ang II–treated Lox+/+ vessels, medial CD68+ cells were asso-
ciated with the first 2 elastic layers nearest to the intima. Medial CD68+ cells in the aorta of Lox+/Mu animals 
treated with Ang II, however, were in the outer layers of the media closest to the adventitia (Figure 2C).
Evaluation of  factors that adversely affect vessel wall integrity and SMC function. An explanation for why Lox+/Mu 
mice are more sensitive than WT animals to Ang II infusion was explored by first checking for possible differ-
ences in Ang II receptor expression using quantitative PCR (qPCR). In ascending aorta from Lox+/Mu mice, all 3 
Ang II receptors (Agtr1a, Agtr1b, and Agtr2) were detected, and there was no difference in their expression levels 
Figure 2. Ang II treatment leads to changes in vascular cellularity and infiltration of immune cells. (A) Frozen 
sections of descending aorta from Lox+/+ and Lox+/Mu animals following 28 days of treatment with Ang II or saline 
(asterisks indicate vessel lumen; scale bars: 5 μm). Macrophages (stained green, arrowheads) were detected with 
an antibody to CD68, and cell nuclei were visualized with DAPI. Red is elastin autofluorescence. The vessel wall was 
thicker in both Lox+/+ and Lox+/Mu animals following Ang II treatment, with more DAPI+ and CD68+ cells in the adven-
titia of both genotypes. (B) In the medial layer, there were fewer SMCs in the aorta of WT animals treated with Ang 
II but more cells in Lox+/Mu aorta. Shown are the mean ± SD for cell number counts between the internal and external 
elastic lamina on 7 tissue sections from each group. Two-way ANOVA with Tukey’s multiple-comparisons test, with 
the 2 variables being genotype and treatment, was used to assess differences. Data are presented as mean ± SD. *P 
< 0.05, **P < 0.01. (C) Medial CD68+ cells were mostly located on the luminal side of the media in the Lox+/+ aorta but 
nearer the adventitia in Lox+/Mu aorta after Ang II treatment.
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compared with WT controls (Supplemental Figure 2A). Thus, the potential for Ang II receptor–mediated sig-
naling is similar in both genotypes.
Many Ang II–induced responses on SMCs are attributable to stimulation of  NADPH oxidase with the 
subsequent generation of  ROS (21, 22). We used dihydroethidium, a cell-permeable compound that inter-
acts with superoxide, to assess oxidant levels in sections of  WT and mutant ascending aorta and found no 
difference between the 2 genotypes (Supplemental Figure 2B). Thus, differences in levels of  oxidative stress 
do not appear to be a factor in the Ang II susceptibility of  Lox+/Mu mice.
In many models of  aortic disease, the presence of  proteases that degrade elastin can initiate and prop-
agate disease by degrading the elastic fiber system in the vessel wall. We therefore investigated whether 
3 elastolytic MMPs commonly linked to vascular remodeling — MMP2, MMP9, and MMP12 — were 
differentially expressed in mutant versus WT aorta. There were no differences in Mmp2 and Mmp9 mRNA 
expression levels, while expression of  Mmp12 was diminished in the mutant aorta (Supplemental Figure 2C).
Active LOX is absent in LoxMu/Mu mouse embryonic fibroblast conditioned medium. To elucidate how the M292R 
modification affects LOX function, we used mouse embryonic fibroblasts (MEFs) from WT, KO, and mutant 
animals to characterize LOX secretion and activity. Mutant cells were indistinguishable from WT cells in 
morphology and in their rate of proliferation (data not shown). LOX activity (Figure 3A), assessed using an 
Amplex Red assay, was not detected in cell layer extracts of any MEF genotype (Lox+/+, Lox+/Mu, LoxMu/Mu, and 
Lox–/–), which was expected, since the full-length intracellular form of LOX (pro-LOX) is an inactive zymogen. 
LOX enzymatic activity was readily detected in the conditioned medium from Lox+/+ MEFs and showed linear 
enzyme kinetics over the period of the Amplex Red assay. Conditioned medium from LoxMu/Mu MEFs, however, 
had no detectable activity, similar to conditioned medium from cells with inactivated Lox alleles (Lox–/–) (Figure 
3B). Activity was detected in conditioned medium from Lox+/Mu cells, where the linearity and rate of substrate 
oxidation were comparable to those seen in Lox+/+ cells, indicating that the mutant form of the protein does not 
adversely affect the enzymatic activity of WT LOX and hence does not function in a dominant negative fashion.
M292R LOX is poorly secreted and is retained in the ER. LOX is maintained as an inactive 50-kDa 
proenzyme through every stage of  the synthetic and secretory pathway. Activation requires secretion 
into the extracellular space, where proteolytic removal of  the N-terminal propeptide portion of  the 
protein generates the 30-kDa active catalytic domain. To determine whether LOX activity is absent in 
M292R MEF conditioned medium because mutant LOX is not secreted, we performed Western blots 
using an anti-LOX antibody on Lox+/+, Lox+/Mu, and LoxMu/Mu MEF cell layers and conditioned medi-
um. Immunoblotting showed increased levels of  50-kDa intracellular pro-LOX protein in cell extracts 
from LoxMu/Mu MEFs compared with Lox+/+ cells (Figure 4A). Conversely, there was abundant 30-kDa 
mature (processed) LOX in conditioned medium from WT cells but barely detectable levels in medium 
from LoxMu/Mu MEFs (Figure 4B). These findings indicate that the mutant protein is poorly secreted and 
is retained intracellularly as the proenzyme.
Figure 3. LOX enzymatic activity is absent in LoxMu/Mu cells. (A) LOX activity in cell lysates from Lox+/+, Lox+/Mu, LoxMu/Mu, 
and Lox–/– mouse embryonic fibroblasts measured using the Amplex Red assay over 150 minutes and expressed as relative 
fluorescence units (RFU). As expected, LOX activity was not detected in any of the cell extracts, as intracellular LOX is 
catalytically inactive until proteolytically processed outside of cells. (B) LOX activity in conditioned medium from the same 
cells as in A. LOX activity was detected in Lox+/+ and Lox+/Mu cells, but was absent in conditioned medium from LoxMu/Mu 
MEFs. Cells from Lox–/– animals served as a negative control. Repeated measures 2-way ANOVA with Tukey’s multiple-com-
parisons test was used to assess differences between groups at each time point. Values are mean ± SD. *P < 0.05, ****P < 
0.0001, Lox+/+ vs. LoxMu/Mu.
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Immunofluorescence imaging with an antibody to LOX showed minimal intracellular staining in 
Lox+/+ cells, confirming that WT LOX is secreted efficiently (Figure 5A). Staining of  LoxMu/Mu cells, how-
ever, showed abundant intracellular staining, consistent with the immunoblot results described above. The 
staining pattern for intracellular LOX was typical of  accumulation within the ER, which was confirmed by 
colocalization of  LOX with calnexin, an ER-resident protein (Figure 5, B and C).
A direct interaction between LOX and calnexin was shown using coimmunoprecipitation from Lox+/+, 
Lox+/Mu, and LoxMu/Mu MEF lysates. Lox–/– cells served as the negative control. Cell lysates were immuno-
precipitated with an anti-calnexin antibody, followed by immunoblotting using an antibody to LOX. LOX 
protein was detected in calnexin immunoprecipitates from all genotypes except Lox–/–, confirming an inter-
action between the 2 proteins (Figure 5D).
M292R LOX has an altered protein conformation. The high level of LOX detected in LoxMu/Mu MEF calnexin 
immunoprecipitates suggests that M292R LOX is misfolded and trapped in the ER bound to calnexin. To 
determine whether M292R LOX is conformationally different from the WT enzyme, we explored possible 
structural changes by assessing differential sensitivity to proteolytic degradation. Changes in protein structure 
frequently expose or mask protease binding sites, leading to altered degradation products and a different deg-
radation fingerprint. Immunoblotting of cell lysate from Lox+/+, Lox+/Mu, and LoxMu/Mu MEFs incubated at 37°C 
for 6 hours to exploit protein degradation by endogenous enzymes within the cell lysate showed time-depen-
dent degradation of WT but not M292R LOX (Figure 6). These results suggest that WT and M292R pro-LOX 
have different susceptibilities to degradation arising from cell-associated proteases. Differential degradation 
was also observed when cell lysates were incubated with pancreatic elastase. In digests of Lox+/+ cell lysate, 
there was a 25-kDa fragment evident with all doses of elastase that was absent in LoxMu/Mu samples (Supplemen-
tal Figure 3, arrow). When treated with the highest dose of elastase, pro-LOX from Lox+/+ and Lox+/Mu samples 
degraded predominantly to a 30-kDa fragment. LOX from LoxMu/Mu samples, in contrast, degraded further to 
mainly a 10-kDa fragment. It is important to note that pancreatic elastase does not cleave after methionine or 
arginine, so the Met-to-Arg mutation does not create or negate a protease cleavage site for this enzyme. Togeth-
er, the conformational difference between the WT and mutant proteins suggests that M292R LOX is misfolded, 
which is consistent with its protracted interaction with calnexin in the ER.
M292R LOX does not elicit an ER stress response. Accumulation of misfolded proteins in the ER generally 
leads to ER stress, which subsequently activates the unfolded protein response (UPR) (23). UPR triggers 3 
primary stress sensors, PERK, IRE1, and ATF6. Under resting conditions, BIP/Grp78 maintains these sensors 
in an inactive state. Upon ER stress, BIP binds to misfolded proteins, thereby allowing for sensor activation. To 
determine whether the continuous presence of misfolded mutant LOX induces ER stress, we assessed Bip tran-
script levels by qPCR. We also measured mRNA levels of Atf4 and Chop, downstream transcriptional activators 
of the PERK pathway. Atf4 and Chop were not elevated in LoxMu/Mu MEFs compared with Lox+/+ cells (Figure 
7, A and B). While there was a statistically significant increase in Bip mRNA in mutant cells (Figure 7C), the 
Figure 4. Mutant LOX is retained inside the cell. (A) Immunoblotting of MEF lysate with an antibody to LOX shows 
increased amounts of pro-LOX (50 kDa) in LoxMu/Mu cells compared with Lox+/+ MEFs. (B) Immunoblots of conditioned 
medium demonstrate less processed LOX (30 kDa) associated with LoxMu/Mu cells, which is consistent with LOX reten-
tion within the cell. β-Actin– and Ponceau S–stained gel blots served as loading controls.
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~20% change was modest compared with the ~2-fold and ~4-fold increase in Atf4 and Chop, respectively, when 
ER stress was stimulated by treatment of MEFs with lopinavir/ritonavir, which served as a positive control 
(data not shown). Electron microscopic analysis of WT and mutant cells showed that ER volume was not 
markedly different in the 2 cell types (Supplemental Figure 4), suggesting that mutant protein does not accumu-
late to levels that would produce dilated saccules. Together, these results suggest that LOX protein containing 
the M292R mutation does not induce substantial ER stress.
Increased activation of  autophagy in LoxMu/Mu cells. The absence of  ER stress in LoxMu/Mu cells was surprising 
given that M292R LOX does not leave the ER. To determine whether mutant LOX is being removed from 
the ER for degradation through the lysosomal pathway, we costained cells for LOX and the lysosomal 
marker LAMP-2. No colocalization of  the 2 proteins was observed, suggesting that the mutant protein was 
not trafficked through lysosomes (Supplemental Figure 5).
Autophagy is a general mechanism for clearing proteins accumulating in cells. Clearing of  misfolded 
proteins from the ER, a process termed ER-phagy, plays a critical role in ER homeostasis (24). To deter-
mine whether mutant LOX directly activates autophagy-mediated protein clearance from the ER, we mea-
sured 2 autophagy activation markers, p62 and microtubule-associated protein 1A/1B, light chain 3 (LC3), 
in WT and LoxMu/Mu MEFs. Following pretreatment with bafilomycin A1 (BafA1) to inhibit organelle acid-
ification–induced degradation of  p62 and LC3, only LoxMu/Mu cells with and without BafA1 pretreatment 
had significantly increased p62 expression compared with Lox+/+ cells without BafA1 pretreatment (Figure 
8, A and B). The autophagy activation markers LC3-I and -II were also elevated in mutant compared with 
WT cells (Figure 8, A, C, and D), providing more evidence for increased autophagy.
We also used electron microscopy to screen for the presence of  autophagosome-like vesicles in WT 
and mutant cells (Supplemental Figure 4). We observed that multi- and single-membrane vesicles typical of  
autophagosomes were particularly abundant in the perinuclear region but were also present throughout the 
cytoplasm of  LoxMu/Mu cells. Such structures were rare in WT cells. Together, the existence of  autophagic 
vesicles along with increased expression of  autophagy activation markers in mutant cells is consistent with 
the clearance of  misfolded mutant LOX from the ER through an autophagy/proteasome pathway.
Mutant LOX does not influence the secretion of  the WT protein. To assess whether the secretion of  WT LOX 
is affected by the presence of  M292R mutant protein, we transiently expressed plasmids containing WT 
LOX, and M292R LOX fused to the fluorescent protein mApple, in Lox–/– MEFs. Successful transfection 
Figure 5. Intracellular mutant LOX interacts with ER-resident protein calnexin. (A) Immunofluorescence imaging of Lox+/+, Lox+/Mu, and LoxMu/Mu mouse 
embryonic fibroblasts (MEFs) using an anti-LOX antibody showed intracellular accumulation of mutant but not WT LOX protein. (B) Imaging using an anti-
body to calnexin showed a uniform distribution of intracellular calnexin staining in all cells. (C) Merged images of LOX and calnexin staining established colo-
calization of intracellular mutant LOX with calnexin. Scale bars: 1 μm (D) Cell lysates from Lox+/+, Lox+/Mu, LoxMu/Mu, and Lox–/– MEFs were immunoprecipitated 
with anti-calnexin antibody, separated by SDS-PAGE, then immunoblotted with an anti-LOX antibody. Both WT and mutant LOX were immunoprecipitated 
with calnexin, but the level of calnexin-bound mutant LOX was much higher than that of WT LOX. Cell lysate from Lox–/– cells served as a negative control.
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was confirmed by intracellular mApple expression using fluorescence imaging (data not shown). In the 
conditioned medium of  Lox–/– cells transfected with empty plasmid, no LOX was observed by Western blot 
analysis (Figure 9A). In Lox–/– MEFs transfected with 2.5 μg WT Lox-mApple plasmid, an immunoreactive 
protein band at approximately 60 kDa was detected in the conditioned media, corresponding to the size 
of  active LOX (30 kDa) fused to mApple (27 kDa). In Lox–/– MEFs transfected with 2.5 μg of  M292R 
Lox-mApple plasmid, LOX protein was observed inside the cell by fluorescence microscopy, but no LOX 
protein was detected in conditioned medium by Western blotting, consistent with the inability of  M292R 
LOX to be secreted. To determine whether mutant LOX alters the secretion of  the WT protein, or if  the 
WT protein acts as a chaperone to facilitate the secretion of  the mutant protein, we cotransfected cells 
with 1.25 μg each of  WT and mutant plasmid, which is half  as much as was used for single plasmid trans-
fection. If  mutant LOX does not affect the secretion of  the WT protein, then LOX should be detected in 
conditioned medium, but at half  the level of  the single plasmid transfection. If  the mutant protein has an 
adverse effect on WT LOX secretion, then levels will be lower than 50%. If  WT LOX acts as a chaperone to 
facilitate secretion of  the mutant protein, then the combination of  both secreted proteins would be higher 
than 50% and possibly equivalent to the WT transfection (1.25 + 1.25 = 2.5 μg). Figure 9 shows that LOX 
protein was detected in conditioned medium of  doubly transfected cells at half  the level of  singly transfect-
ed cells, confirming that the mutant protein does not affect the secretion of  WT LOX.
M292R propeptide processing. Our experimental results are consistent with the M292R mutation being a 
loss-of-function phenotype due to a secretion defect. The final activation step of  the proenzyme occurs out-
side the cell through proteolytic separation of  the propeptide and catalytic domains. To determine whether 
M292R pro-LOX could be processed to the 30-kDa mature form if  it were secreted, we incubated cell 
lysates from WT and mutant MEFs with recombinant BMP1 (rBMP1), the enzyme responsible for propep-
tide cleavage. Western blot analysis showed that BMP1 appropriately processed both WT and M292R pro-
LOX to the 30-kDa mature form (Supplemental Figure 6). Thus, the mutation did not inhibit propeptide 
processing. The processed mutant protein was not assayed for oxidase activity because intracellular LOX in 
M292R MEFs does not have bound copper and cannot be enzymatically active.
Discussion
LOX plays a critical role in vascular ECM maturation by catalyzing the crosslinking of  elastin and fibrillar 
collagens, the 2 major ECM protein classes in the aortic wall. Phylogenic studies suggest that the current 
form of  vertebrate LOX coevolved with elastin and helped facilitate the appearance of  a closed circulatory 
system (12, 25). Therefore, it is no surprise that mutations in LOX give rise to vascular insufficiency and 
disease. All LOX mutations associated with TAAD in humans show autosomal dominant inheritance, and 
most result in loss of  function. We know from mouse studies that inactivation of  both Lox alleles is lethal 
and that other members of  the LOX family cannot assume LOX’s critical role in vascular development and 
maintenance of  the vessel wall. In this report, we utilize a mouse model of  a well-characterized human 
mutation to explore how LOX haploinsufficiency leads to vascular dilation and aneurysm formation.
Figure 6. M292R Lox mutation leads to altered protein conformation. (A) Cell lysates from Lox+/+ and LoxMu/Mu mouse 
embryonic fibroblasts were incubated at 37°C, and samples were collected every hour for 6 hours. Immunoblotting with 
an anti-LOX antibody showed more extensive degradation of WT LOX compared with the mutant protein. (B) Quantita-
tion of band density from immunoblot in A.
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Mice heterozygous for the Lox M292R variant (Lox+/Mu) have increased elastic lamellar fragmenta-
tion in the wall of  the ascending aorta (3), but do not develop aortic dilation under normal conditions. 
The absence of  aneurysmal disease was surprising given that humans heterozygous for this same muta-
tion are prone to aneurysm formation and vessel wall changes (3). Variability in the age of  disease onset 
and disease severity in humans, however, suggested that a secondary challenge is a factor in disease 
initiation and progression. Here we show that hypertension induced by Ang II infusion resulted in vessel 
wall changes in both Lox+/+ and Lox+/Mu mice, but only Lox+/Mu animals showed aortic dilation localized to 
the ascending aorta. Several groups have reported that the effects of  Ang II are most pronounced in the 
ascending aorta region in this model (26–28), but the underlying factors governing this vessel specificity 
are unknown. Differences in the embryonic origin of  the cells that populate the aortic wall are one expla-
nation (29, 30), but the composition and maturation of  the aortic ECM are also factors. In Lox+/Mu mice, 
changes in ECM crosslinking associated with LOX insufficiency could have more negative consequences 
for this vessel segment because of  high collagen and elastin levels and the high mechanical stress experi-
enced by the aortic wall during the cardiac cycle.
While several Ang II–induced vascular changes were expected (19, 27) and common to WT and 
mutant animals, there were also significant differences. For instance, medial expansion was evident in both 
genotypes, but the effect was most notable in mutant mice, in which there was an increase in the number 
of  smooth muscle cells between the elastic lamellae. This response is particularly unusual, since the intral-
amellar space is typically populated by a single smooth muscle cell layer, as can be seen in vessels from 
saline-treated Lox+/+ and Lox+/Mu animals (Figure 2). The opposite change occurred in WT vessels, where 
there were fewer smooth muscle cells in response to Ang II, suggesting Ang II–related apoptosis or growth 
suppression (26), which we did not assess.
Figure 7. M292R LOX does not elicit an ER stress 
response. qPCR showing transcript levels of the ER 
stress markers (A) Atf4, (B) Chop, and (C) Bip nor-
malized to Gapdh expression in mouse embryonic 
fibroblasts from Lox+/+, Lox+/Mu, and LoxMu/Mu mice. One-
way ANOVA with Tukey’s multiple-comparisons test 
was used to assess differences, which were minimal 
between the 3 genotypes. Data are presented as mean 
± SD. ***P < 0.001.
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Another cellular change in the ascending and descending aorta following Ang II treatment was the 
accumulation of  macrophages in the aortic wall of  both WT and Lox+/Mu mice. CD68+ cells were found in 
the adventitia of  both genotypes, with fewer cells in the medial layer. In Ang II–treated WT mice, CD68+ 
cells accumulated in the intima and inner elastic layers of  the media and did not localize to breaks in 
elastic lamella, as has been reported in other models (18, 20). Their location within the wall, however, 
shows that some cells were able to penetrate past the internal elastic lamina into the first or second layer 
of  smooth muscle cells. Medial CD68+ cells in Lox+/Mu mice exposed to Ang II, in contrast, were local-
ized to the outer aspect of  the media and occurred at higher numbers than in WT vessels. These results 
suggest that the cellular origin of  the CD68+ cells or the route of  inflammatory cell infiltration is different 
in Lox+/+ and Lox+/Mu vessels as a response to wall stress.
The location of  macrophages in the outer region of  the wall provides a mechanistic explanation 
for why Lox+/Mu, but not WT, aorta dilates following Ang II treatment. ECM degradation is a prima-
ry factor leading to vessel wall dilation. Elastases and other matrix-degrading enzymes secreted by 
macrophages destabilize the vessel wall, particularly when matrix degradation occurs in or near the 
adventitia — the vessel compartment essential for maintaining the structural integrity of  the artery 
(31). The medial cell hypertrophy and inflammatory cell accumulation in the Lox+/Mu aorta in response 
to hemodynamic stress are similar in several ways to vascular changes in mouse models of  Marfan 
syndrome with mutations in fibrillin-1, a key elastic fiber protein. In Marfan mice, inflammatory cell 
accumulation at the medial-adventitial interface correlates with increased elastin degradation and a loss 
Figure 8. Intracellular mutant LOX activates the autophagy markers p62 and LC3. (A) Mouse embryonic fibroblasts 
(MEFs) were pretreated with bafilomycin A1 (BafA1) to prevent organelle acidification–induced degradation of auto-
phagy activation markers. Immunoblots were then used to detect P62 and LC3 isoforms in MEF lysates. (B) Quanti-
fication of the detected proteins showed a significant increase in p62 only in cell lysates of LoxMu/Mu MEFs with and 
without BafA1 treatment compared with Lox+/+ MEFs without BafA1. (C and D) Also, LC3 was elevated in LoxMu/Mu 
cells compared with Lox+/+ cells. Two-way ANOVA with Tukey’s multiple-comparisons test, with the 2 variables being 
genotype and treatment, was used to assess differences. Data are presented as mean ± SD. *P < 0.05, **P < 0.001.
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of  structural integrity that leads to vessel wall dilation (32). As in the Ang II–treated Lox+/Mu animals, 
only the ascending aorta is affected in Marfan mice.
Our previous studies showed that mice with the Lox M292R mutation share numerous phenotypic 
traits with Lox+/– animals (3), suggesting that M292R is a loss-of-function mutation in mice and humans. 
Even though the amino acid change is in the catalytic domain of  LOX close to the copper binding site, it 
was not clear whether the mutation results in a catalytically dead enzyme or if  some other aspect of  LOX 
processing is negatively affected by the mutation. Our data show that the answer fits both possibilities: the 
mutant protein is retained in the ER and not secreted, and the enzyme is catalytically dead because of  its 
inability to traffic to the Golgi, where it needs to bind copper and form the redox quinone cofactor LTQ 
required for catalytic activity (33). Even though we found that the propeptide of  mutant pro-LOX could be 
cleaved by rBMP1 similarly to WT LOX, full-length LOX in the ER cannot be catalytically active even if  
propeptide processing does occur.
Why mutant LOX is retained in the ER is not clear, but our data point to protein misfolding as a prob-
able cause. ER retention is characteristic of  incompletely folded proteins. Folding intermediates of  most 
secreted proteins interact with the calnexin/calreticulin protein complex in the ER to achieve the prop-
er native conformation required for secretion (34). The calnexin/calreticulin protein complex recognizes 
N-linked glycan structures (LOX has 3 N-linked glycosylation sites in the propeptide region; ref. 11) that 
undergo cycles of  sugar residue removal and addition. Once folded correctly, calnexin and calreticulin dis-
sociate, and the folded proteins are transported from the ER to the Golgi apparatus. Mutant LOX colocal-
ized intracellularly with calnexin and was isolated bound to calnexin in cellular extracts, suggesting that the 
protein remains misfolded despite repeated folding interactions with calnexin. Furthermore, the differential 
susceptibility to proteolytic degradation of  mutant compared with WT LOX is consistent with structural 
differences between the 2 proteins.
It was interesting that mutant LOX accumulation in the ER did not induce an appreciable UPR. We 
saw no upregulation in mutant cells of  the ER stress–related markers Bip (an ER luminal chaperone protein 
and critical ER stress sensor), Atf4 (a transcription factor downstream of  PERK that plays a crucial role in 
the adaptation to ER stress), or Chop (a transcription factor regulated by ATF4 that drives proapoptotic gene 
transcription). Nor could we detect in mutant cells an increase in ER volume frequently associated with ER 
stress. One pathway whereby ER stress is mitigated is removal from the ER of  mutant protein and degrada-
tion at the lysosome (ERAD-II) or proteasome (ERAD-I) (24). We were unable to localize LOX within lyso-
somes but did find increased expression of  the autophagy markers p62 and LC3. Electron microscopy also 
identified an increased number of  autophagic vesicles in LoxMu/Mu cells. These results suggest that misfolded 
mutant LOX is being cleared from the ER through an autophagy/proteasome pathway and would explain 
why mutant protein levels never reached a critical threshold to sustain an ER stress response. Furthermore, 
there is mounting evidence that the autophagy and secretory pathways are coregulated and intimately linked 
(35), which may represent a mechanistic connection into the LOX trafficking defect that we identified. 
Figure 9. Mutant LOX does not interfere with secretion of the WT protein. Lox–/– mouse embryonic fibroblasts were transiently transfected with WT 
or mutant LOX fused to the fluorescent reporter mApple, and protein in conditioned medium from transfected cells was separated by SDS-PAGE. (A) 
Immunoblotting using an antibody to LOX showed that protein from the WT LOX construct is properly secreted, while mutant (Mu) LOX is not. When the 
WT and mutant LOX constructs were cotransfected into Lox–/– cells at half the level of the single transfections, the amount of secreted protein that was 
detected was equivalent to that expected from the WT allele, suggesting that the presence of mutant LOX does not alter the secretion of the WT protein. 
The bottom panel is an image of the stained gel to document equal sample loading. (B) Quantification of the LOX bands in A. 
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It should be noted that all the experiments probing the fate of  the mutant protein were done in cultured cells. 
It is possible, but unlikely, that in vivo, in tissues, and at developmental stages relevant to the TAAD pheno-
type, LOX folding, secretion, ER retention, and stress occur differently than in MEFs.
Guo et al. (15) described 2 other LOX active site variants (S280R and S348R) that segregate with dis-
ease in families with TAAD. When expressed from transgenes in HeLa cells and examined in cell lysates, 
a portion of  the pro-LOX protein was processed to its active form and was able to oxidize substrate at rates 
approximately equivalent to the WT enzyme (S348R) or with approximately 50% lower activity (S280R) 
(2, 15). Enzymatic activity in conditioned medium from the transfected cells was not evaluated, so it is not 
known whether these LOX variants are efficiently secreted. However, the fact that the proteins are catalyti-
cally active implies trafficking through the Golgi and proteolytic removal of  the propeptide domain. Thus, 
unlike the M292R mutation, which is retained in the ER, the S348R and S280R variants appear capable 
of  traversing the secretory pathway. How these proteins, which have full (or somewhat reduced) catalytic 
activity, cause thoracic aortic disease is an interesting question. An intriguing possibility is that the mutant 
proteins contribute to disease pathogenesis through mechanisms that do not involve their amine oxidase 
activity. Noncatalytic functions for LOX are emerging (5, 36, 37), and much remains to be learned about 
how mutations in this multifunctional enzyme lead to aortic disease.
Methods
Antibodies. Antibodies used in this study are described in Supplemental Table 1.
Mouse models and cell isolation. A knockin mouse strain bearing the Lox M292R substitution was gener-
ated in the C57BL/6 background using CRISPR/Cas9 genome editing technology as previously described 
(3). Lox+/– mice in the same background are described in ref. 6. Primary MEFs were isolated from the 
various mouse lines by digestion of  E14.5 mouse embryos with trypsin/EDTA at 37°C for 30 minutes in 
DMEM (38). Cells were collected by centrifugation and grown in DMEM, 10% FBS, 1% penicillin/strep-
tomycin, and 1 mM l-glutamine.
Ang II treatment and blood pressure measurements. Telemetry transmitters (Data Sciences International, model 
PA-C10) were implanted surgically in 3- to 4-month-old mice under isoflurane anesthesia. The catheter was 
inserted in the left common carotid artery and advanced to the aortic arch, and the transmitter was placed subcu-
taneously along the abdomen. Animals were allowed to recover for 7 days prior to activation of transmitters, and 
continuous recording of heart rate and arterial pressure was obtained, with sampling every 5 minutes for 15-sec-
ond intervals for 3 days. Data were collected and stored using Dataquest ART (Data Sciences International).
After baseline blood pressure measurements were obtained, mice were implanted with osmotic pumps 
(Alzet model 1004, DURECT Corp.) that delivered Ang II (MilliporeSigma) subcutaneously at a dose of  
2 μg/kg/min in the interscapular region, according to published procedures (39, 40). Mice infused with 
saline were used as controls. After a week of  Ang II treatment, arterial pressure and heart rate were again 
continuously recorded using the telemeters, with sampling every 5 minutes for 15-second intervals for 3 
days. Animals were fed a standard laboratory chow diet. After 28 days, animals were sacrificed under 
isoflurane anesthesia, and vessels were collected for compliance studies and histological characterization.
Vessel compliance measurement. For vessel compliance measurements, the ascending aorta and left com-
mon carotid artery were excised and placed in a physiological saline solution. Vessels were then cleaned of  
surrounding fat and connective tissue and mounted onto a pressure arteriograph (Danish Myo Technolo-
gy). Experiments were done at 37°C in an organ bath containing physiological saline. The mounted vessels 
were visualized using a computerized imaging system, allowing continuous recording of  vessel diameters. 
Vessel outer diameters were recorded while intravascular pressure was increased from 0 to 175 mmHg by 
increments of  25 mmHg (12 seconds per step). The average of  3 outer diameter measurements was taken 
at each pressure (40, 41).
Protein quantification, hydroxyproline, and desmosine assays. Each ascending aorta was hydrolyzed at 105°C 
overnight with 20 μL of  6 N hydrochloric acid (Thermo Fisher Scientific) and dried under vacuum in a 
SpeedVac. The dried pellet was dissolved in 400 μL water and filtered with a 0.45-μm filter. Total protein, 
hydroxyproline, and desmosine levels were determined as described previously (42).
Dihydroethidium staining for superoxide detection in aortic sections. Superoxide in aortic sections was detected 
using dihydroethidum (DHE) staining. In the presence of  superoxide, DHE is oxidized to 2-hydroxyethid-
ium, which is highly fluorescent and intercalates within the DNA, staining the nucleus a fluorescent red 
(43, 44). After euthanasia and thoracotomy, the right atrium was clipped, and 5 mL cold (4°C) 1× PBS 
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was flushed through the left ventricle to clear the blood. Ascending aorta was then dissected, placed in 
Tissue-Tek O.C.T. Compound (Sakura Finetek), and flash frozen in liquid nitrogen. Four-micrometer cryo-
sections were obtained using a Leica CM1850 cryostat and placed on charged microscope slides (Thermo 
Fisher Scientific). A 10-mM stock solution of  DHE (Life Technologies) in DMSO was diluted to 10 μM 
using 1× PBS. The 10-μM DHE solution was applied to unfixed aortic sections and incubated at 37°C for 
30 minutes in the dark. After staining with DHE, sections were then rinsed with 1× PBS for 5 minutes at 
room temperature (RT) and mounted with a coverslip using ProLong Diamond Antifade Mountant with 
DAPI (Invitrogen). Images were obtained on the Zeiss Axioscope fluorescence microscope with a QIm-
aging MicroPublisher 3.3 RTV camera using QCapture software (QImaging). The entire procedure (from 
mouse euthanasia to image acquisition) occurred within 8 hours.
Immunofluorescence on aortic sections and area measurements. Ascending and descending aortas were dissect-
ed as above and placed in O.C.T. compound, and the blocks were frozen on dry ice. Four-micrometer-thick 
cryosections were placed on glass slides and stored at –80°C. The sections were fixed in 4% paraformaldehyde 
(Electron Microscopy Sciences) in 1× PBS at 4°C for 10 minutes, washed twice with 1× PBS (5 minutes each) 
at RT, and blocked with a solution containing 1% BSA (MilliporeSigma), 1% fish gelatin (MilliporeSigma), 
and 0.05% Triton-X (Acros Organics) in 1× PBS for 1 hour at RT. The aortic sections were then incubated 
with rat anti–mouse CD68 antibody (Bio-Rad) at a 1:1000 dilution in blocking solution at 4°C overnight. 
The next day, sections were washed 3 times with 1× PBS (5 minutes each) and incubated in goat anti-rat IgG 
Alexa Fluor 488 secondary antibody (Thermo Fisher Scientific) diluted 1:2000 and DAPI diluted 1:3000 in 
blocking solution at RT for 1 hour. The sections were washed twice with 1× PBS (5 minutes each) at RT, 
mounted with a coverslip using ProLong Diamond Antifade Mountant, and imaged using the Axioscope 
fluorescence microscope equipped with the QImaging MicroPublisher 3.3 RTV camera using QCapture soft-
ware as above. For area measurements, frozen sections from the descending aorta from 3-month-old mice 
were prepared as described above. The area between the internal and external elastic laminae was traced in 
each ×40 image using ImageJ software (NIH) and measured in pixels2.
LOX activity assay. MEFs were grown in 10-cm dishes and maintained as above until fully confluent. 
Twenty-four hours before collection, culture medium was replaced with DMEM lacking phenol red and FBS, 
supplemented with 50 μg/mL ascorbic acid and 0.1% BSA. Conditioned medium from each dish was con-
centrated using Amicon Ultra-15 Centrifugal Filter Units (Millipore) to a final volume of  1 mL. Cell lysates 
were collected by scraping in 1× PBS containing protease inhibitors. LOX activity in cell lysate and concen-
trated culture medium, incubated with and without the LOX inhibitor β-aminopropionitrile (BAPN), was 
quantified using the Amplex Red assay as previously described (3, 45). Resorufin fluorescence, the product of  
Amplex Red oxidation, was measured at excitation and emission wavelengths (540 and 600 nm, respectively) 
every 30 minutes for 150 minutes using a BioTek H4 Hybrid Reader. LOX activity was calculated as the differ-
ence between total activity and activity in the presence of  BAPN. Differences in relative fluorescent units were 
tested using 2-way ANOVA with Tukey’s multiple-comparisons test.
Immunofluorescence imaging of  primary cells. Primary MEFs were seeded in 4-chamber glass slides at 3 
× 105 cells per/well. After 3 days in culture, the cells were fixed with cold methanol (2 washes, 5 seconds 
each) followed by 3 washes with blocking solution containing 1× PBS, 1% BSA, 1% fish gelatin (Milli-
poreSigma), and 0.05% Triton-X100 at pH 7.4, then incubated in blocking solution for 30 minutes at RT. 
The cells were then incubated with a primary antibody to LOX at 1:1000 in blocking solution overnight at 
4°C. After washing the cells with blocking solution to remove the primary antibody, the cells were incubat-
ed with a goat anti-rabbit IgG Alexa Fluor 568 secondary antibody at 1:2000 (Thermo Fisher Scientific) 
and anti-calnexin primary antibody directly labeled with Alexa Fluor 488 at 1:4000 in blocking solution for 
30 minutes at RT. The cells were washed with blocking solution 3 times, then mounted using ProLong Dia-
mond Antifade Mountant (Invitrogen) and coverslipped. The samples were imaged using the Axioscope 
fluorescence microscope and QCapture Pro software.
Protein extraction from cell culture and aortic tissue. Cultured MEFs were switched to serum-free medium 
24 hours before protein extraction. MEFs in 10-cm dishes were incubated in 1 mL lysis (RIPA) buffer 
(MilliporeSigma) containing protease inhibitors for 30 minutes at 4°C. The lysates were scraped from the 
dish into microfuge tubes and centrifuged at 17,500 g for 5 minutes, and the supernatant was collected. 
Conditioned medium from each dish was concentrated using Amicon Ultra-15 Centrifugal Filter Units 
(Millipore) to a final volume of  1 mL. The protein concentration in cell lysates and concentrated media 
was measured using bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). Laemmli buffer with and 
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without DTT was added to samples for SDS-PAGE and native gel electrophoresis, respectively. Only the 
samples with DTT were boiled at 100°C for 5 minutes.
RNA extraction and qPCR. RNA was extracted from confluent cell cultures using TRIzol (Thermo Fisher 
Scientific) following the manufacturer’s protocol. For RNA isolation from aortic tissue, ascending aorta from 
adult Lox+/+ and Lox+/Mu mice were each homogenized in 500 μl TRIzol using QIAGEN TissueLyser. The man-
ufacturer’s protocol was followed for RNA isolation. At the time of RNA precipitation, 10 μg glycogen (Mil-
liporeSigma) was added as a carrier to each sample. Each RNA pellet was dissolved in 10 μL molecular-grade 
water. The RNA was quantified using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). One 
microgram of the isolated RNA was treated with DNase I (Invitrogen) according to the manufacturer’s instruc-
tions. Reverse transcription was then carried out using the High-Capacity RNA-to-cDNA Kit (Applied Bio-
systems). One microliter of cDNA was used for qPCR using TaqMan Fast Universal PCR Master Mix and 
TaqMan assay primer/probes (Life Technologies) for Bip (Mm00517691_m1), Atf4 (Mm00515325_g1), Chop 
(Mm01135937_g1), Agtr1a (Mm01957722_s1), Agtr1b (Mm02620758_s1), Agtr2 (Mm00431727_91), Mmp2 
(Mm00439498_m1), Mmp9 (Mm00442991_m1), Mmp12 (Mm00500554_m1), and Gapdh (Mm9999999915_
g1), which was used as an internal control. Ten-microliter reactions were performed in duplicate using a ViiA 7 
Real-Time PCR System for Bip, Atf4, and Chop and QuantStudio 3 Real-Time PCR system (Applied Biosystems) 
for Agtr1a, Agtr1b, Agtr2, Mmp2, Mmp9, and Mmp12. All mRNA levels were normalized to Gapdh expression.
rBMP1 treatment. Protein was extracted from Lox+/+, Lox+/Mu, and LoxMu/Mu MEFs as described above. 
Fifty microliters of  cell lysates from cultured MEFs containing 50 μg total protein were incubated with 
30, 60, and 90 ng rBMP1 (R&D Systems) for 45 minutes at 37°C in reaction buffer (50 mM Tris, 150 mM 
NaCl, 5 mM CaCl2, pH 7.5). The enzyme reaction was stopped by adding Laemmli buffer with DTT and 
incubated at 100°C for 3 minutes before analysis by SDS-PAGE and immunoblotting.
Western blotting. Protein extracts from cells, concentrated condition medium, or tissues (generally 50 μg) 
were analyzed using 10% Mini-PROTEAN TGX Stain-Free Protein Gels (Bio-Rad) run at 100 mV for 1 
hour. The protein was then transferred to ProBlott Membrane (Applied Biosystems). The blots were incubat-
ed in 5% nonfat dried milk in 0.1% 1× PBS-Tween for 1 hour at RT, then incubated with a primary antibody 
overnight at 4°C. The next day, the blots were washed with 0.1% 1× PBS-Tween and incubated in ECL 
anti-rabbit or anti-mouse IgG HRP-Linked Secondary Antibody (GE Healthcare) for 1 hour at RT. The blots 
were then washed and the immunoreactive bands detected using Immobilon Western Chemiluminescent 
HRP Substrate (Millipore). The blots were stripped by incubating in 2% SDS, 75 mM Tris-HCl, and 100 mM 
β-mercaptoethanol for 1 hour at 65°C while shaking. The blot was then incubated in 0.1% 1× PBS-Tween 
wash buffer for 1 hour at RT before immunodetection of  β-actin (MilliporeSigma) at 1:20,000 in wash buffer, 
which was used as a loading control. For protein samples from concentrated conditioned media, membranes 
were stained with Ponceau S solution (MilliporeSigma) before blocking and used as a loading control. Alter-
natively, stain-free images of  Mini-PROTEAN TGX Stain-Free Protein Gels (Bio-Rad) taken following the 
manufacturer’s protocol served as a loading control.
Coimmunoprecipitation. Cell lysates were prepared from MEFs 5 days after confluency as described 
above. Immobilized protein A anti-rabbit IgG beads (50 μL), preequilibrated by washing with lysis buffer, 
were then added to 250 μL cell extract. After incubation on a rocking platform for 60 minutes at 4°C, the 
sample was centrifuged at 2500 g for 3 minutes, and the supernatant was incubated with 8 μg immunopre-
cipitation antibody for 1 hour at 4°C. Fifty microliters of  precleared protein A beads was then added, and 
the samples incubated overnight at 4°C with rocking. Immune complexes bound to the protein A beads 
were collected by centrifugation and washed with lysis buffer prior to boiling at 100°C for 10 minutes with 
Laemmli buffer containing DTT. The supernatant was collected by centrifugation, and proteins were sepa-
rated by SDS-PAGE and immunoblotted following the same protocol described above.
Protein degradation analysis. Confluent cultures of  WT and mutant MEFs were treated with 5 μg/mL 
Brefeldin A (MilliporeSigma) to inhibit protein transport from ER to the Golgi apparatus. This ensured that 
WT LOX remained in the cells so that the starting amount of  protein was the same across genotypes. After 
4 hours, the cell lysate was extracted using lysis buffer placed at 37°C to initiate protein degradation. Every 
hour, 50 μL aliquot of  cell lysate was collected, then immediately boiled with Laemmli sample buffer at 100°C 
for 5 minutes prior to SDS-PAGE analysis. For exogenous protease-mediated degradation, human pancreatic 
elastase in increasing concentrations (0.625, 1.25, 2.5, 5 ng/μL) was added to cell lysates containing 1 mg/
mL protein at 4°C for 30 minutes. After treatment, elastase activity was inhibited with protease inhibitor cock-
tail, and samples were boiled with Laemmli sample buffer at 100°C for 5 minutes for SDS-PAGE analysis.
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Autophagy markers. Confluent MEFs in 6-well dishes were pretreated with 100 mM BafA1 (MilliporeSig-
ma) for 3 hours before cell lysates were collected. The protein samples were separated on 4%–15% gradient 
gels for SDS-PAGE analysis. Immunoblotting was performed following the same procedure as above.
Lox-mApple plasmid cloning and expression. The mouse Lox cDNA in a mammalian expression vector driven by 
a pCMV promoter was purchased from GE Healthcare. The Lox open reading frame was PCR amplified using a 
5′ primer bearing an XhoI restriction enzyme site (5′-CAGATCTCGAGAGCGTTTCGCCTGGGCTGTGC-3′) 
and a 3′ primer designed to remove the Lox stop codon bearing a BamHI restriction enzyme site (5′-GGATCCA-
CATACGGTGAAATTGTGCAGCCTGAG-3′). The PCR product and the pGEMT shuttle vector (Promega) 
were digested with XhoI and BamHI, then ligated together using T4 ligase. The mutant Lox plasmid bearing the 
893 T>G base pair change was generated using the Lox-pGEMT plasmid as the template, using the Phusion 
Site-Directed Mutagenesis Kit (Thermo Fisher Scientific), following the manufacturer’s protocol (5′-TTACCA-
CAGCAGGGACGAATTCAGCCACTATG-3′ and 5′-TGTTGGTGACAGCTGTGCCACTCCC-3′). The 
WT and mutant Lox-pGEMT plasmid sequences were confirmed using Sanger sequencing performed at the 
Washington University Protein and Nucleic Acid Chemistry Laboratory. To generate the Lox-mApple plasmids, 
WT and mutant Lox pGEMT plasmids and the mApple plasmid (46), provided by David W. Piston (Wash-
ington University School of Medicine in St. Louis), were digested with XhoI and BamHI restriction enzymes. 
The WT and mutant mLox cDNA inserts were then ligated into mApple vectors to generate the mLox-mApple 
fusion plasmids and sequenced to confirm. To express the WT and mutant Lox–mApple plasmids in MEFs, 
Lipofectamine 3000 reagents (Thermo Fisher Scientific) were used following the manufacturer’s protocol.
Transmission electron microscopy. MEFs from Lox+/+, Lox+/Mu, and LoxMu/Mu mice, cultured on glass coverslips, 
were washed in cacodylate buffer (0.15 M cacodylate in 2 mM CaCl2, pH 7.4) and fixed for 5 minutes with 
2.5% glutaraldehyde and 2% paraformaldehyde in cacodylate buffer prewarmed to 37°C. The samples were 
then incubated at RT for an additional hour, washed with cacodylate buffer, and treated with 1% OsO4/1.5% 
potassium ferrocyanide for 1 hour in the dark. After washing with ultrapure water, en bloc staining was per-
formed in 2% uranyl acetate for 1 hour in the dark. The samples were washed again in ultrapure water before 
dehydration in a graded acetone series. Finally, the samples were embedded in Epon resin and cured in a 60°C 
oven for 48 hours. The processed samples were imaged using a JEOL 1400 electron microscope.
Statistics. One-way ANOVA with Tukey’s multiple-comparisons test was used to determine the signifi-
cance, if  any, between different groups, particularly genotypes. When 2 variables were present, e.g., genotype 
and treatment or genotype and gene, 2-way ANOVA with Tukey’s multiple-comparisons test was used to assess 
differences. If  the same sample was measured repeatedly (e.g., at different pressures in the pressure-diameter 
curves in Figure 1, C and D, or at different time points in Figure 3), then repeated measures 2-way ANOVA 
with Tukey’s multiple-comparisons test was performed. Prism 8 for Mac OS X (GraphPad Software) was used 
to run statistical analyses. In all numerical figures, data are presented as mean ± SD. P < 0.05 was considered 
statistically significant. The statistical test used and significant differences are noted in each figure legend.
Study approval. All animal experiments were carried out following protocols approved by Washington 
University School of  Medicine Institutional Animal Care and Use Committee.
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